SEARCH BY

Issuer directory Issuer directory
KEYWORDS
COMPANIES / ISIN
TYPE OF INFORMATION
INDUSTRY

Start search  ADVANCED SEARCH

COMPARTMENTS / INDICES

France
America
Asia
Oceania
Africa
Europe

S&P 100 NEWS

FEEDS

My RSS My Google Microsoft Live My Yahoo

COMPANY SEARCH RESULT

Biogen Idec Inc: Click to view the issuer\'s details

Last update : 21/08/2018  >View issuer details

2022.01.04 | 13:34 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA - HTML (w)

2021.12.22 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Japan’s First Committee on New Drugs of The Pharmaceutical Affairs and Food Sanitation Council Seeks Additional Data; Aducanumab Remains under Review - HTML (w)

2021.12.20 | 13:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early Alzheimer’s Disease - HTML (w)

2021.12.17 | 12:43 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Update on Regulatory Submission for Aducanumab in the European Union - HTML (w)

2021.12.16 | 13:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Update on the Phase 4 Confirmatory Study of ADUHELM® - HTML (w)

2021.12.14 | 13:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience - HTML (w)

2021.11.17 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Update on Regulatory Review of Aducanumab in the European Union - HTML (w)

2021.11.16 | 15:20 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce The European Commission Grants Marketing Authorization for VUMERITY® (diroximel fumarate) as Oral Treatment for Relapsing-Remitting Multiple Sclerosis - HTML (w)

2021.11.16 | 01:44 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development - HTML (w)

2021.11.15 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year - HTML (w)

2021.11.11 | 23:10 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce New Phase 3 Data Show Positive Correlation Between ADUHELM™ Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer’s Disease - HTML (w)

2021.11.03 | 12:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting - HTML (w)

2021.10.17 | 22:20 | Permanent Information Releases / Sales and Revenues

English version HTML (w) Mail

puce Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS - HTML (w)

2021.10.14 | 22:06 | Permanent Information Releases / Sales and Revenues

English version HTML (w) Mail

puce Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting - HTML (w)

2021.10.13 | 12:05 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce New Data at ECTRIMS 2021 Highlight Biogen’s Focus on Patient-Centered Outcomes and Improving the MS Patient Experience - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 181